Celcuity
| General Information | |
| Business: | We are a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Our proprietary CELx diagnostic platform is the only commercially ready technology we are aware of that uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it.
|
| Industry: | MEDICAL LABORATORIES |
| Employees: | 15 |
| Founded: | 2012 |
| Contact Information | |
| Address | 16305 36th Avenue N., Suite 450, Minneapolis, MN 55446, US |
| Phone Number | (763) 392-0123 |
| Web Address | http://www.celcuity.com |
| View Prospectus: | Celcuity |
| Financial Information | |
| Market Cap | $92.4mil |
| Revenues | $0 mil (last 12 months) |
| Net Income | $-4.5 mil (last 12 months) |
| IPO Profile | |
| Symbol | CELC |
| Exchange | NASDAQ |
| Shares (millions): | 2.4 |
| Price range | $9.50 - $9.50 |
| Est. $ Volume | $22.8 mil |
| Manager / Joint Managers | Craig-Hallum Capital Group |
| CO-Managers | - |
| Expected To Trade: | 9/20/2017 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |